The DOI matches its Crossref record.
Pharmacological Treatments for Hypochondriasis: A Review
Abstract
Despite the high prevalence of hypochondriasis in primary care settings, there are relatively few pharmacotherapy trials in hypochondriasis. Ongoing controversy about nosology of hypochondriasis and lack of work demonstrating specific neurobiological alterations in hypochondriasis may contribute to this. There have been several open label trials of selective serotonin reuptake inhibitors (SSRIs) and serotonin-2A antagonist/reuptake inhibitors (SARIs) for the treatment of hypochondriasis, and more recently two randomized controlled trials (RCTs). Taken together, there is a small body of evidence to support the efficacy of SSRIs in the treatment of hypochondriasis. Further RCTs are needed to confirm efficacy, determine effectiveness of treatments in primary care settings, address influence of comorbidity and other potential predictors of outcome, and compare pharmacotherapy to psychotherapy. Keywords: Hypochondriasis, neurobiology, open label trial, pharmacotherapy, randomized clinical trial, selective serotonin reuptake inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several psychological and pharmacological treatments have notable effects on traits that overlap with the psychological response present in SSD, including health anxiety, anxiety sensitivity, and pain catastrophizing.
“Moreover, several psychological and pharmacological treatments have notable effects on traits that overlap with the psychological response that is present in SSD, for example, in terms of health anxiety, 34,35 anxiety sensitivity, 36,37 and pain catastrophizing.38,39”
From Symptom Preoccupation in Fibromyalgia: Prevalence and Correlates of Somatic Symptom Disorder in a Self-Recruited Sample (2020) · cites this paper as [34]
Citations
Cited by
Sorted by citations
Axelsson, E., & Hedman-Lagerlöf, E. (2019) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2019.1703182 · Cited by 96
“Although many patients with health anxiety respond to antidepressant medication [16], most prefer psychological treatment [17] and as in the case of most anxiety and obsessive-compulsive spectrum disorders, cognitive behavior therapy (CBT) based on exposure and response prevention [18] or cognitive restructuring techn…”
BackgroundAxelsson, E., Hedman-Lagerlöf, M., Hedman-Lagerlöf, E., Ljótsson, B., & Andersson, E. (2020) · Psychosomatics · doi:10.1016/j.psym.2020.01.012 · Cited by 23
Salehi, C., Kershaw, K. A., Storer, B., Newby, J. M., & Murphy, M. J. (2024) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2024.100209 · Cited by 3
Murphy, M. J., Storer, B., Kershaw, K. A., Begg, H. E., Burdekin, P., Harvey, S. B., Millard, M., Sharma, S. K., Salehi, C., & Newby, J. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4458107/v1
Metadata
- Authors
- Louw, K.-A., Hoare, J., & Stein, D.
- Affiliations
- Groote Schuur Hospital (ZA)
- Corresponding author
- Stein, Dan
- Venue
- Current Psychiatry Reviews
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-01-31
- Volume
- 10
- Issue
- 1
- Pages
- 70-74
- ISSN
- 1573-4005 (ISSN-L)
- OpenAlex
- W2137628435
- Cited by
- 4
- References
- 0
- Citations by year
- 2024: 2 · 2020: 1 · 2019: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Psychiatry Reviews (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Jazz Pharmaceuticals
- Servier
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- health anxiety, pharmacotherapy, selective serotonin reuptake inhibitors, disease classification, neurobiology, primary care, comorbidities, psychotherapy comparison
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
